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The activity of natural killer (NK) cells is partially regulated by
killer cell immunoglobulin-like receptors (KIRs) interacting
with human leukocyte antigen C (HLA-C) ligands.1 The
ligands of several inhibitory (2DL and 3DL) and activating
(2DS and 3DS)KIR have been described.2 Clinical observations
of hepatitis B virus (HBV) infection reveal that some cases
progress to liver failure, fibrosis, cirrhosis and hepatocellular
carcinoma, whereas infection resolution occurs in other cases.
However, the mechanisms involved in the susceptibility or
resistance to HBV are not completely understood.
Study subjects were recruited from a blood bank, COLSAN-
Associac¸a˜o Beneficente de Coleta de Sangue (Sa˜o Paulo,
Brazil), during the period between January 2010 and
December 2010. We selected 20 occult HBV infection (OBI)
cases and 40 spontaneous HBV resolvers (SHRs). As control
subjects, we enrolled 80 healthy blood donors and 42 HBV
carriers (HBsAg1, anti-HBc1 and detectable HBV DNA).
The study was approved by the Ethics Committee of the
Federal University of Sao Paulo, Brazil, and all study participants
signed an informed consent. Sera were screened for anti-HBc
and HBsAg using a commercial chemiluminescent microparti-
cle immunoassay (Abbott, Wiesbaden, Germany). A commer-
cial test was used for the detection of HBVDNA (HBVMonitor;
Roche, Nutley, NJ, USA). An HBcAg-specific T-cell response, ex
vivoNK cell activity assay and enzyme-linked immunospot assay
for interferon-gamma were performed as previously described.3
The cytokines tumor-necrosis factor-alpha (TNF-a), IL-1, IL-6,
IL-8, IL-10 and IL-12 were evaluated using cytometric bead
array assays (human Th1/Th2 cytokine kit; BD Biosciences,
San Diego, CA, USA). IL-2, IL-4 and IL-18 assays were performed
using an enzyme immunoassay (BioLegend, San Diego, CA,
USA). HLA-C and KIR genotyping was performed using a
Luminex MultiAnalyte profiling system (One Lambda, Inc.,
Canoga Park, CA, USA) with the LABType SSO OneLambda
typing kit (One Lambda, Inc.). KIR locus typing was per-
formed to detect the presence or absence of 15 known KIR
genes, including 2DL1-5, 2DS1-5, 3DL1-3, 3DS1 and the pseu-
dogene KIR3DP1.
The T-cell response is thought to be a key factor determining
the outcome of infection, and it has been shown that chronic
HBV is associated with the presence of dysfunctional immune
responses.4 Within this context, we observed that SHRs pre-
sented a higher magnitude of HBcAg-specific T-cell responses
(Stimulation Index (SI)5SI562.3, P,0.0001) in comparison to
HBV carriers (SI525.4) and OBI cases (SI526.2).
The role of NK cells in viral clearance during acute HBV infec-
tion is also supported by previous reports showing that early high
interferon-gamma production by NK cells may contribute to ini-
tial control of the infection and allow the timely development of an
adaptive immune response.1,5,6 In this study, INF-c production by
T cells was measured to observe the regulatory effect of T cells on
NK cell activity via INF-c. Higher NK cell activity (93%63.1%,
P50.005) was observed in SHRs compared to HBV carriers
(58%62.5%) andOBI cases (57%62.3%), and INF-c production
byTcellswashigher inSHRs (185262.2 Intracytoplasmic cytokine
staining (ISCs)/106 PBMCs, P,0.0001) compared to OBI cases
(65362.0 ISCs/106 PBMCs) and HBV carriers (68562.3 ISCs/
106 PBMCs). Higher T-cell responses and INF-c production cor-
related with higher NK cell activity (P,0.0001). However, the
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opposite scenariowas observed in cases ofHBVpersistence: lowT-
cell responses, INF-c production andNK cell activity (P,0.0001).
We then assessed whether cytokines other than INF-c have
an influence on this immunological scenario and found that
IL-8 and IL-12 serum levels were significantly increased in
HBV carriers (920.861.1 pg/ml and 1008610.1 pg/ml, respect-
ively) and OBI cases (803.761.0 pg/ml and 1110613.0 pg/ml,
respectively) compared to SHR (471.265.0 pg/ml, P,0.0001,
respectively). In a recent study, it has been demonstrated that
IL-12 can facilitate immune evasion andmaintain the persistence
Table 1A Immune parameters results in health blood donors, HBV carrier, OBI and spontaneous HBV resolvers
Study groups
Immune parameter Health blood donors HBV carrier OBI Spontaneous HBV resolvers
HBc specific T-cell response SI,3.0 Median SI525.4 Median SI526,2 Median SI562,3***
NK cell activity 20%61.2% 58%62.5% 57%62.3% 93%63.1***
INF-c production by ELIspot 8–21 ISCs/106 187–685 ISCs/106 141–653 ISCs/106 1110–1852 ISCs/106***
IL-1 levels 0.560.2 pg/ml 3.761.5 pg/ml 3.861.4 pg/ml 4.961.2 pg/ml
IL-2 levels 1.760.2 pg/ml 8.261.7 pg/ml 7.761.3 pg/ml 15.261.9 pg/ml*
IL-4 levels 2.360.8 pg/ml 108.361.8 pg/ml* 102.361.1 pg/ml* 84.761.6 pg/ml
IL-6 levels 0.760.2 pg/ml 28.461.3 pg/ml** 27.161.1 pg/ml** 7.861.0 pg/ml
IL-8 levels 0.860.3 pg/ml 920.861.1 pg/ml** 803.763.0 pg/ml** 369.468.0 pg/ml
IL-10 levels 0.260.2 pg/ml 4.161.8 pg/ml 3.561.2 pg/ml 5.361.7 pg/ml
IL-12 levels 0.560.4 pg/ml 1008610.1 pg/ml*** 1110613.0 pg/ml*** 471.265.0 pg/ml
IL-18 levels 98.1610.2 pg/ml 245.668.3 pg/ml 301.866.7 pg/ml 489.6610.2 pg/ml*
INF-c levels 1.360.8 pg/ml 58.362.8 pg/ml 62.361.1 pg/ml 175.761.0 pg/ml**
TNF-a levels 0.560.3 pg/ml 652.3611.3 pg/ml 753.168.9 pg/ml 1465611.0 pg/ml***
Abbreviations: ELIspot: enzyme-linked immunospot assay for IFN-c; IFN-c : interferon-gamma; IL: interleukin; OBI: occult hepatitis B infection; TNF-a:
tumor-necrosis factor-alpha.
HBV carrier and OBI patients vs. spontaneous HBV resolvers: ***P,0.0001; **P,0.001; *P,0.05.
Table 1B Frequency of KIR genes and HLA-C1 and HLA-C2 in health blood donors, HBV carrier, OBI and spontaneous HBV
resolvers
Study groups
KIR gene and HLA-C
Health blood donors
n/total (frequency%)
HBV carrier
n/total (frequency%)
OBI
n/total (frequency%)
Spontaneous HBV resolvers
n/total (frequency%)
2DL1 39/80 (48.7%) 20/42 (47.6%) 9/20 (45.0%) 18/40 (450%)
2DL2 41/80 (51.2%) 21/42 (50.0%) 10/20 (50.0%) 19/40 (47.5%)
2DL3 41/80 (51.2%) 29/42 (52.4%) 9/20 (45.0%) 37/40 (92.5%)**y
2DL4 37/80 (46.2%) 19/42 (45.2%) 10/20 (50.0%) 20/40 (50.0%)
2DL5 38/80 (47.5%) 20/42 (47.6%) 9/20 (45.0%) 19/40 (47.5%)
2DP1 40/80 (50.0%) 22/42 (52.4%) 11/20 (55.0%) 21/40 (52.5%)
2DS1 42/80 (52.5%) 39/42 (92.8%)**y 18/20 (95.0%)**y 14/40 (35.0%)
2DS2 39/80 (48.7%) 21/42 (50.0%) 10/20 (50.0%) 22/40 (55.0%)
2DS3 37/80 (46.2%) 28/42 (66.6%) 13/20 (65.0%) 25/40 (62.5%)1
2DS4 35/80 (43.7%) 20/42 (47.6%) 11/20 (55.0%)¥ 20/40 (50.0%)
3DL1 32/80 (40.0%) 18/42 (42.8%) 9/20 (45.0%) 21/40 (52.5%)1
3DL2 36/80 (45.0%) 22/42 (52.3%) 12/20 (60.0%)¥ 19/40 (47.5%)
3DL3 33/80 (41.2%) 19/42 (45.2%) 9/20 (45.0%) 19/40 (47.5%)
3DP1 41/80 (51.2%) 21/42 (50.0%) 11/20 (55.0%) 25/40 (62.5%)1
3DS1 36/80 (45.0%) 25/42 (59.5%)y 9/20 (45.0%) 21/40 (52.5%)
HLA-C1C2 39/80 (48.7%) 21/42 (50.0%) 9/20 (45.0%) 19/40 (47.5%)
HLA-C1 homozygous 51/80 (63.7%) 39/42 (92.8%)** 19/20 (95.0%)** 14/40 (35.0%)
HLA-C2 homozygous 53/80 (66.2%) 37/42 (88.1%)y 16/20 (80.0%) 38/40 (95.0%)*
Abbreviations: HBV, hepatitis B virus; HLA-C, human leukocyte antigen C; KIR, killer cell immunoglobulin-like receptor; OBI: occult hepatitis B
infection.
HBV carrier and OBI patients vs. spontaneous HBV resolvers: **P,0.001; *P,0.05.
Health blood donors vs. HBV carrier: yP,0.05.
Health blood donors vs. OBI: ¥P,0.05.
Health blood donors vs. spontaneous HBV resolvers: 1P,0.05.
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of HBV,7 and it has also been observed that IL-8may influence the
inflammatory process during the pathological stage of hepatitis B
infection.8 Both studies correlated IL-8 and IL-12 with the
persistence of HBV DNA, corroborating the findings reported
in the current study. IL-4 production in OBI cases (102.36
1.1 pg/ml) and HBV carriers (108.361.8 pg/ml) compared to
SHRs (84.761.6 pg/ml) were significant, agreeing with pre-
vious studies that reported a relationship between IL-4 pro-
duction and viral persistence in hepatitis B infection.9
Serum levels of IL-6 were also increased in OBI cases
(17.161.1 pg/ml) and HBV carriers (18.461.3 pg/ml) com-
pared to SHRs (7.861.0 pg/ml) (P,0.05). Serum IL-6 levels
have been reported to be elevated in individuals with chronic
hepatitis B infection, cirrhosis and hepatocellular carcinoma,10
and serum IL-6 levels were in agreement with this reported rela-
tionship between this cytokine and the progression of HBV infec-
tion. INF-c and IL-2 serum levels increased in SHRs (175.76
1.0 pg/ml and 15.261.9 pg/ml, respectively) compared to HBV
carriers (58.362.8 pg/ml and 8.261.7 pg/ml, respectively) and
OBI cases (62.361.1 pg/ml and 7.761.3 pg/ml, respectively).
Both INF-c and IL-2 may be a stimulus for the activation of
NK cells and higher levels of T-lymphocyte activation, and both
cytokines correlate with control of HBV infection. Another
major cytokine, IL-18, has also been reported to be involved
with resistance to HBV infection.11 In this study, SHR showed
higher IL-18 serum levels (489.6610.2 pg/ml) compared to
OBI cases (301.866.7 pg/ml) and HBV carriers (245.66
8.3 pg/ml). IL-18 is mediated by INF-c production, which is
also high in the serum of SHRs. TNF-a serum levels were sig-
nificantly increased in SHRs (1465611.0 pg/ml) compared to
HBV carriers and OBI cases (652.3611.3 pg/ml and 753.16
8.9 pg/ml, respectively; P,0.0001).
TNF-a is an extremely critical cytokine for host immune
responses to viral infection. Indeed, circulatory TNF-a levels
increase during HBV infection,10 and increased hepatic TNF-a
production is associated with the suppression of HBV replica-
tion in transgenic mice expressing HBV in the liver.12
Altogether, the NK cell activity, HBcAg-specific T-cell res-
ponses and cytokine patterns observed in this study suggest that a
balance of the magnitudes of these immune responses determines
susceptibility versus resistance to HBV (Tables 1A and 1B). In
SHRs, a significant HBcAg-specific T-cell response and high
TNF-a levels correlated with high NK cell activity (Odds Ratio
(OD)52.65, P,0.0001) and the absence of viral DNA
(OR52.03, P,0.0001). In OBI cases and HBV carriers, high IL-
8 and IL-12 levels correlatedwith lowNK cell activity andHBcAg-
specific T-cell responses (OR51.99, P,0.001) and the presence of
viral DNA (OR52.78, P,0.001). Serum levels of IL-1 and IL-10
were similar in the presence (OBI cases and HBV carriers) or
absence (SHRs) of HBV DNA, a result that is in contrast to what
has been previously described. A previous study demonstrated a
key role for IL-1 in the progression of HBV-mediated disease due
to an IL-1 polymorphism.13
With regard to the mechanism accounting for this immuno-
logical pattern in the presence or absence of HBV DNA, it is
surprising that the immunological profile (T-cell response, NK
cell activity and cytokine production) obtained in the HBV
DNA-positive (OBI cases and HBV carriers) and HBV DNA-
negative groups (SHR) were associated with the frequency of a
specific pattern ofKIR andHLA-C (OR52.87, P50.0001). The
frequency of blood donors with HLA-C2 homozygosity was
higher in OBI cases (50.6%) compared to SHRs (35.8%); a
reciprocal association of HLA-C1 homozygosity with SHRs
(92% in resolved versus 80.2% in persistent infection) was also
observed. The presence ofKIR2DL1 andKIR2DL2 (both inhib-
itory receptors) was observed in all the studied groups, and
also, the KIR2DL3 activation receptor was found at a high
frequency (92.8%) in SHRs in the current study. In SHRs,
the interaction between KIR2DL3 and HLAC1 homozygosity
(high affinity) was associated with highNK cell activity, HBcAg
T-cell responses and significant TNF-a production (OR52.91,
P50.0001).
The interaction between KIR2DS1 and HLAC2 homozygosity
was related to persistent infection17, as we observed an asso-
ciation of HBV carriers and OBI cases with low NK cell activity
and HBcAg T-cell responses and high production of IL-6, IL-8
and IL-12. HLA-C1C2 was present in all of the studied groups
and did not demonstrate a specific relationship. It has been
reported that KIR2DL3:HLA-C1 homozygosity was protective
in a Chinese population,14 whereas KIR2DL1:HLA-C2 was
associated with HBV infection susceptibility according to sub-
sequent findings.15,16 Unfortunately, studies of KIR/HLA-C
interactions in Brazilian populations are focused on auto-
immune diseases and infectious diseases other than hepatitis B.
In summary, the interaction between KIR genes and HLA is
important for determining antiviral immunity and contributes
to the protection against or susceptibility to HBV infection.
Further research is required to describe other immunological
and molecular mechanisms related to susceptibility to or pro-
tection from hepatitis B infection.
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